Financials

v3.21.2
Condensed Consolidated Balance Sheets - USD ($)
Sep. 30, 2021
Dec. 31, 2020
Current Assets    
Cash and cash equivalents $ 22,901,784 $ 19,444,737
Accounts receivable 19,566 7,118
Prepaid expenses 898,186 303,178
Other current assets 598,442 576,660
Total Current Assets 24,417,978 20,331,693
Property and equipment, net 5,081,207 5,171,134
Operating lease right-of-use assets 263,440 326,085
Intangible assets, net 240,954 321,641
Total Assets 30,003,579 26,150,553
Current Liabilities    
Accounts payable 1,181,917 1,539,547
Accrued liabilities 3,607,809 3,491,740
Management and directors' fees payable 91,213 55,174
Current portion of long-term debt 759,507 841,319
Current portion of finance lease liabilities 51,950 59,930
Current portion of operating lease liabilities 124,872 179,624
Current portion of grant repayable 34,731 69,218
Total Current Liabilities 5,851,999 6,236,552
Long-term debt, net of current portion 2,027,882 2,606,885
Finance lease liabilities, net of current portion 532,301 601,967
Operating lease liabilities, net of current portion 143,998 151,828
Grant repayable, net of current portion 266,813 259,603
Total Liabilities 8,822,993 9,856,835
STOCKHOLDERS' EQUITY    
Common Stock Authorized: 100,000,000 shares of common stock, at $0.001 par value Issued and outstanding: 53,223,761 shares and 48,607,017 shares, respectively 53,224 48,607
Additional paid-in capital 150,221,335 126,526,239
Accumulated other comprehensive income (loss) 8,732 (59,978)
Accumulated deficit (128,953,498) (110,173,971)
Total VolitionRx Limited Stockholders' Equity 21,329,793 16,340,897
Non-controlling interest (149,207) (47,179)
Total Stockholders' Equity 21,180,586 16,293,718
Total Liabilities and Stockholders' Equity $ 30,003,579 $ 26,150,553
v3.21.2
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Revenues        
Royalty $ 0 $ 0 $ 0 $ 2,112
Product 25,483 575 75,795 4,201
Total Revenues 25,483 575 75,795 6,313
Operating Expenses        
Research and development 4,445,877 3,180,177 11,968,424 10,567,988
General and administrative 2,426,854 1,080,308 6,053,613 4,292,666
Sales and marketing 715,044 244,510 1,601,816 734,355
Total Operating Expenses 7,587,775 4,504,995 19,623,853 15,595,009
Operating Loss (7,562,292) (4,504,420) (19,548,058) (15,588,696)
Other Income (Expenses)        
Grant income 419,271 0 810,803 98,870
Gain / ( Loss) on disposal of fixed assets 0 200,393 (26,167) 293,595
Interest income 290 2,801 2,503 48,956
Interest expense (38,767) (34,722) (120,636) (91,105)
Total Other Income 380,794 168,472 666,503 350,316
Net Loss (7,181,498) (4,335,948) (18,881,555) (15,238,380)
Net Loss attributable to Non-Controlling Interest 45,065 8,050 102,028 23,396
Net Loss attributable to VolitionRx Limited Stockholders (7,136,433) (4,327,898) (18,779,527) (15,214,984)
Other Comprehensive (Loss) / Income        
Foreign currency translation adjustments (20,875) (573,397) 68,710 (273,791)
Net Comprehensive Loss $ (7,202,373) $ (4,909,345) $ (18,812,845) $ (15,512,171)
Net Loss Per Share - Basic and Diluted attributable to VolitionRx Limited $ (0.13) $ (0.09) $ (0.36) $ (0.34)
Weighted Average Shares Outstanding        
- Basic and Diluted 53,166,781 47,027,011 52,355,681 44,148,793
v3.21.2
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Operating Activities    
Net loss $ (18,881,555) $ (15,238,380)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization 708,520 525,150
Amortization of operating lease right-of-use assets 148,075 194,749
Loss (Gain) on disposal of fixed assets 26,167 (293,595)
Stock-based compensation 2,393,568 981,992
Common stock issued for Director compensation in Volition Germany 0 333,969
Changes in operating assets and liabilities:    
Prepaid expenses (595,008) (177,354)
Accounts receivable (12,416) (573)
Other current assets (20,010) (274,398)
Accounts payable and accrued liabilities (27,183) 365,167
Management and directors' fees payable (36,749) 47,672
Right-of-use assets operating leases liabilities (147,924) (194,146)
Net Cash Used In Operating Activities (16,444,515) (13,729,747)
Investing Activities:    
Purchases of property and equipment (844,987) (679,782)
Proceeds from sales of property and equipment 0 97,388
Net Cash Used In Investing Activities (844,987) (582,394)
Financing Activities:    
Net proceeds from issuances of common stock 21,436,571 19,200,954
Tax withholdings paid related to stock-based compensation (130,426) (187,465)
Common stock repurchased 0 (54,434)
Proceeds from grants repayable 37,631 3,802
Proceeds from long-term debt 79,614 0
Payments on long-term debt (571,616) (356,701)
Payments on grants repayable (47,789) (41,257)
Payments on finance lease obligations (43,881) (83,221)
Net Cash Provided By Financing Activities 20,760,104 18,481,678
Effect of foreign exchange on cash (13,555) (207,976)
Net Change in Cash 3,457,047 3,961,561
Cash and cash equivalents - Beginning of Period 19,444,737 16,966,168
Cash and cash equivalents - End of Period 22,901,784 20,927,729
Supplemental Disclosures of Cash Flow Information:    
Interest paid 120,636 91,105
Non-Cash Financing Activities:    
Common stock issued on cashless exercises of stock options 102 118
Offering costs from issuance of common stock $ 125,494 $ 1,229,169
arrow-downarrow-leftarrow-rightarrowchevron-downcircle-link--redcircle-linkcloseplayplus